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Tuberculosis Laboratory 
Cooperative Agreement: 
Annual Aggregate Report, 2008 
Inaugural Report 
The Laboratory Capacity Activity in the Mycobacteriology Laboratory Branch (MLB) in the 
Division of Tuberculosis Elimination (DTBE) is pleased to introduce the first edition of the 
“Tuberculosis Laboratory Cooperative Agreement: Annual Aggregate Report”. The data 
contained herein are a compilation of the workload and turnaround time for calendar 
year 2008 taken from TB Elimination Cooperative Agreement narratives by public health 
laboratories (PHLs) receiving support via this mechanism.  These data provide an opportunity 
for PHLs to benchmark themselves by comparing their own laboratory data with those from 
peers with similar testing volumes.  Benchmarking may serve as a useful guide for identifying 
testing practices and algorithms that are successful or need examination. 
A few items  must be considered when reviewing this report.  First, the data are self-reported 
by PHLs.  The interpretation of the statistic and the calculation used to derive the reported 
values may differ between laboratories.  Second, although the same data were requested 
from all 58 PHL, not every PHL reported complete data.  In the future, we expect that all PHLs 
will report data for each variable.  Complete reporting is imperative for providing an accurate 
reflection of the work being performed over time to be described in future aggregate reports. 
Third, unless noted otherwise, data are reported on a “per patient” and not “per specimen” 
basis.  Lastly, due to the limitations presented above, this report is to be used only as a guide 
and is not intended for other purposes that may be disciplinary in nature. 
The MLB thanks you for your continued dedication and hard work in providing TB laboratory 
testing services.  We hope that you find this report both interesting and informative.  Please let 
us know if you have any comments, questions, or suggestions that might improve the quality 
of future reports. 
Contact Details 
For inquiries, please contact the laboratory consultant for your jurisdiction. 
1. Angela Starks, PhD—astarks@cdc.gov, (404) 639-3205 
2. Tracy Dalton, PhD—tldalton@cdc.gov, (404) 639–3904 
3. Frances Tyrrell, MPH, MT (ASCP), SM—ftyrrell@cdc.gov, (404) 639-5451 
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TABLE 1. National Workload Data for 
 
 TB Elimination Cooperative Agreement Recipient Labs in 2008.
 
Variable Total  number 
Minimum 
number per site 
Maximum 
number per site 
Number labs
reporting 
Clinical specimens receiveda 295,416 306 23,500 58 
Patients  for whom a clinical  specimen was 118,914 124 10,934 58 
submittedb 
Patients with at least one specimen culture 5,745 1 792 58 
positive for MTBCc 
Patients for whom a reference isolate was 21,250 0 2,575 58 
submittedd 
Patients with at least one reference isolate  3,327 0 276 55 
identified as MTBC 
Patients for whom DSTe for first-line drugs 8,255 2 895 58 
was performed 
Patients for whom clinical specimen was 13,232 0 5,855 57 
tested directly with NAATf or other rapid 
detection test 
Patients NAAT positive for MTBC 2,479 0 567 52 
 
  
  
 
a Processed and cultured, not including isolates referred from other laboratories, b Processed and a TB culture inoculated, 

c Mycobacterium tuberculosis complex, d Received to rule out or confirm the identification of MTBC, 

e Drug susceptibility testing,  f Nucleic acid amplification test
 
Ratio of Total Number of Specimens 
to Number of Patients Tested (N=58) 
Ratio 
Mean = 2.61 
Standard Dev = 1.004 
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50 2.33 
75 3.52 
90 4.10 
Figure 1.
Ratio of total specimens tested to number 
of patients tested. The mean number of 
specimens cultured per patient was 2.61. 
In general, laboratories in high-incidence 
areas have a higher ratio and labs located 
in lower-incidence areas have a lower 
ratio.  A value far in excess of the 10th and 
90th percentiles (<1.59 or >4.10 specimens 
cultured per patient) may suggest that a 
review of laboratory  policies is indicated. 
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Percent of Specimens Received
Within 1, 2, and 3 Days After Collection 
AFB Smear Results Reported within One Day
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Figure 2.
The current goal of laboratory receipt of 
specimens within 1 day of collection  was 
achieved on average 37% of the time in 
state public health labs.  Barriers described 
in cooperative agreement narratives 
included lack of a courier system, difficult 
terrain,  remote locales, and limited 
education to providers.  In addition, receipt 
of specimens can be affected by weekends 
and furlough days. 
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Figure 3.  
Box plot display of the percent of AFB 
smear results reported within one day 
of specimen receipt.  An overwhelming 
majority of cooperative agreement 
recipient labs reported 87% or more of AFB 
smear results within 1 day of specimen 
receipt.  Three laboratories reported values 
that were statistically below the observed 
minimum for other sites. Outliers should 
assess potential reasons for difficulty in 
meeting this objective. 
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Positivity of Direct Detection
Stratified by Testing Volume (N = 39 labs)
Rapid Direct DetectionMethods (N = 58) 
ID from Culture, Primary Methods (N = 58)
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Figure 4.  
Overall, approximately 19% of TB suspects 
with a clinical specimen tested by a 
direct detection method were positive 
for MTBC. The positivity rate declined 
with an increasing number of TB suspects 
examined.  PHL should work with 
submitters and their TB Control Program 
to determine an appropriate testing 
algorithm for utilization of direct detection 
methodologies. 
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Figure 5.  
Methods used by public health laboratories 
for rapid direct detection of MTBC from 
clinical specimens. 
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Figure 6.  
Primary methods used by public health 
laboratories for identification of MTBC 
from culture. 
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Percent ID Reported Within 21 Days of Specimen Receipt 
Stratified by Testing Volume (N=49)
Percent First-line DST Reported Within 28 Days 
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Figure 7.
Many PHLs are near to or exceeding 80% of MTBC identifications being reported within 21 days of specimen receipt by the laboratory.
There were no significant differences in turnaround time based on volume of testing.  Some PHLs challenged in meeting this goal 
reported issues with staffing that limit the number of times ID assays can be performed each week. 
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Overall, 55% of first-line DST results are reported within the recommended 28 days of specimen receipt in the laboratory.  In general, 
PHLs that performed more DST per year reported a higher percentage of results within 28 days.  Barriers to meeting recommended 
TAT should be evaluated to ensure progress of reporting DST results within 28 days of receipt. 
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Figure 9.  
This figure represents the percent of 
cultures positive for MTBC stratified by 
volume of patients tested (not volume 
of total specimens). Overall, positivity 
declined with increasing volume, except for 
labs testing very high numbers;  however 
the differences among volumes were not 
statistically significant (p =.099, Anova test, 
SPSS, v. 17). 
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Figure 10.
This figure represents the percent of 
reference isolates, positive for MTBC, 
stratified by volume of patients tested. 
Similar to Figure 9,  positivity declined 
with increasing volume, except for labs 
testing very high numbers;  however the 
differences among volumes were not 
statistically significant (p =0 .25, Anova 
test, SPSS, v. 17). 
Monitoring the positivity of cultures and 
isolates over  time (i.e., recovery rate of 
MTBC), is a useful performance indicator 
for the laboratory. 
Summary of Key Findings: 
1.	 Overall, PHLs are meeting the recommended TAT for reporting of smear results in one day, and for identification of MTBC within 21 days 

of specimen receipt. However, meeting the CDC recommended TAT of specimen receipt within one calendar day of collection and the 

provision of first-line DST results within 28 days of specimen receipt remain significant challenges.
 
2.	 Due to reporting variability by PHLs,  it is difficult to determine the percent of patients meeting the Healthy People 2010 Goal of reducing 
the average time for a laboratory to confirm and report TB cases (Target: 2 days for 75 percent of cases that are later culture confirmed). 
However, it is evident that PHLs have great difficulty meeting this goal.  PHLs should continue to ensure access to direct detection 
methodologies (e.g., nucleic acid amplification tests) for rapid identification of MTBC from clinical specimens. 
3.	 PHL Cooperative Agreement narratives provide insight into existing barriers for meeting TAT goals. For example, large geographical areas, 
inadequacies in postal delivery methods, lack of state-sponsored courier systems, and the practice of batching specimens all contribute 
to difficulties for timely specimen delivery. Additionally, staffing and scheduling issues, lab practices such as the need to wait for growth 
on solid media, and policies that delay reporting of preliminary results have all been identified as contributing to lengthy TAT for DST. 
4.	 Analyzing both aggregate and individual PHL data may help to identify trends and patterns that inform strategies to reduce barriers.  
These data are useful for advocacy of policy changes and reveal opportunities for operational research.  Data analysis aids in assessment 
of both national recommendations as well as your own PHL performance objectives to ensure they closely reflect goals that are realistic 
and tied to measurable outcomes. 
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